Company Overview of Juno Therapeutics Inc.
Juno Therapeutics Inc., a biotechnology company, develops immunotherapy platforms for the treatment of cancer. Its immunotherapy platforms include chimeric antigen receptors, which target cell surface tumor-associated antigens that are expressed on cancer cells; and T-cell receptors, the molecules that are utilized by T-cells to recognize target antigens, as well as detect alterations in intracellular antigens present in cancer cells. The company was incorporated in 2013 and is based in Seattle, Washington.
307 Westlake Avenue North
Seattle, WA 98109
Founded in 2013
Key Executives for Juno Therapeutics Inc.
Juno Therapeutics Inc. Key Developments
Similar Private Companies By Industry
|Hybritech, Inc.||United States|
|Alopexx Pharmaceuticals, LLC||United States|
|BioQuanta Corp.||United States|
|Boston Biomedical Research Institute, Inc.||United States|
Recent Private Companies Transactions
April 24, 2014
December 3, 2013
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Greater Houston Partnership||United States|
Post a JobJobs
- Westborough, MA | PallPosted: Jul 17
- Boston, MA | Gen9 BioPosted: Jun 19
- New York City, NY | Bloomberg - Entertainment and Media IndustryPosted: Jul 14
- San Francisco, CA | Presented By Raindance PartnersPosted: Jul 16
Sponsored Financial Commentaries
To contact Juno Therapeutics Inc., please visit junotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.